These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Targeting E3 ubiquitin ligases for cancer therapy. Sun Y Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465 [TBL] [Abstract][Full Text] [Related]
3. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma. Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769 [TBL] [Abstract][Full Text] [Related]
4. E3 ubiquitin ligases as cancer targets and biomarkers. Sun Y Neoplasia; 2006 Aug; 8(8):645-54. PubMed ID: 16925947 [TBL] [Abstract][Full Text] [Related]
5. The SCF-type E3 Ubiquitin Ligases as Cancer Targets. Kitagawa K; Kitagawa M Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120 [TBL] [Abstract][Full Text] [Related]
6. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer. Uchida C; Kitagawa M Curr Cancer Drug Targets; 2016; 16(2):157-74. PubMed ID: 26560116 [TBL] [Abstract][Full Text] [Related]
7. E3 ubiquitin ligases in cancer and implications for therapies. Wang D; Ma L; Wang B; Liu J; Wei W Cancer Metastasis Rev; 2017 Dec; 36(4):683-702. PubMed ID: 29043469 [TBL] [Abstract][Full Text] [Related]
8. A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer. Satija YK; Bhardwaj A; Das S Int J Cancer; 2013 Dec; 133(12):2759-68. PubMed ID: 23436247 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cul1 binding site on the Skp1-F-box interface. Gorelik M; Orlicky S; Sartori MA; Tang X; Marcon E; Kurinov I; Greenblatt JF; Tyers M; Moffat J; Sicheri F; Sidhu SS Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3527-32. PubMed ID: 26976582 [TBL] [Abstract][Full Text] [Related]
10. Molecular targeting of E3 ligases--a therapeutic approach for cancer. Lakshmanan M; Bughani U; Duraisamy S; Diwan M; Dastidar S; Ray A Expert Opin Ther Targets; 2008 Jul; 12(7):855-70. PubMed ID: 18554154 [TBL] [Abstract][Full Text] [Related]
11. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers. Masumoto K; Kitagawa M Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119 [TBL] [Abstract][Full Text] [Related]
12. Role of E3 ubiquitin ligases in gastric cancer. Hou YC; Deng JY World J Gastroenterol; 2015 Jan; 21(3):786-93. PubMed ID: 25624711 [TBL] [Abstract][Full Text] [Related]
13. Targeting E3 Ubiquitin Ligases and Deubiquitinases in Ciliopathy and Cancer. Shiromizu T; Yuge M; Kasahara K; Yamakawa D; Matsui T; Bessho Y; Inagaki M; Nishimura Y Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825105 [TBL] [Abstract][Full Text] [Related]
14. [The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein]. Daks AA; Melino D; Barlev NA Tsitologiia; 2013; 55(10):673-87. PubMed ID: 25509121 [TBL] [Abstract][Full Text] [Related]
15. Overview of approaches for screening for ubiquitin ligase inhibitors. Sun Y Methods Enzymol; 2005; 399():654-63. PubMed ID: 16338387 [TBL] [Abstract][Full Text] [Related]
16. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer. Liu L; Wong CC; Gong B; Yu J Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398 [TBL] [Abstract][Full Text] [Related]
17. Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance. Wang H; Lu Y; Wang M; Wu Y; Wang X; Li Y J Mol Med (Berl); 2021 Feb; 99(2):193-212. PubMed ID: 33392633 [TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-Regulated Cell Proliferation and Cancer. Pérez-Benavente B; Nasresfahani AF; Farràs R Adv Exp Med Biol; 2020; 1233():3-28. PubMed ID: 32274751 [TBL] [Abstract][Full Text] [Related]
19. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery]. Yu Q; Xiong X; Sun Y Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):1-19. PubMed ID: 32621419 [TBL] [Abstract][Full Text] [Related]